New edition of the PORTAL Post (the @portalresearch.org monthly newsletter), featuring lots of great research, including our recent publication about modelling the budget impact of gene therapies to treat sickle cell disease in the US. Check it out here: www.linkedin.com/pulse/octobe...

Excited to share new research led by Jessica Harvey exploring the budget impact of gene therapies for sickle cell disease, with a focus on Medicaid programs. Co-As: @ankurfactorial.bsky.social, @leah-rand.bsky.social, @akesselheim.bsky.social, & George Goshua. 🔗: link.springer.com/article/10.1...

The Common Sense Oncology Fellowship program is now accepting applications. Definitely a great opportunity for anyone interested in health services research and oncology! commonsenseoncology.org/wp-content/u...

Annual trip home to the cottage! #CapeBretonIsland

'The FDA will ask Sarepta to stop shipping its Duchenne muscular dystrophy treatment Elevidys, an HHS official said, in what could be a final blow to the company’s hopes for the product following two patients’ deaths.' via @endpts.com endpoints.news/fda-asks-sar...

'Drugmakers [said] they were stockpiling drugs in the US as a strategy to curb the impact of potential pharma tariffs. In March, Ireland saw a massive 243% increase in pharma exports, compared to the same month last year.' via @annajbrown.bsky.social / @endpts.com endpoints.news/pharmaceutic...

Fantastic postdoc fellowship opportunity @mcgill.ca! mcgill.wd3.myworkdayjobs.com/McGill_Caree...

Always a super interesting read! Notably, amongst the top 20 CEOs, average compensation was greater than $30 million. Total compensation for the top 20 CEOs was more than $600,000,000. Also notable that there is only one woman amongst the top 20. via @andrewedunn.bsky.social / @endpts.com

Just out! The new guidelines from the Canadian Patented Medicine Prices Review Board (PMPRB) have finally been released. Changes to take effect as of January 2026. #hta #drugprices www.canada.ca/en/patented-...

New Health Affairs Forefront by @akesselheim.bsky.social and @jerryavorn.bsky.social from @portalresearch.org about the impact of tariffs on the affordability and availability of medications. www.healthaffairs.org/content/fore...

A little work to make one of the local #Squamish trails a bit more friendly to those riding adaptive mountain bikes.

New in @jama.com, Joseph Daval and I discuss legal issues surrounding ACIP including its role in setting government policy and dealing with politically-motivated agendas arising from its new membership: jamanetwork.com/journals/jam...

The clinical aspect & decision aside, it's problematic for health systems that BioMarin priced Brineura at $1 million. If companies didn't charge these prices, decisions would be easier & less restrictive. Note: Brineura's net sales in 2024 were $170 million (US alone). www.cbc.ca/news/canada/...

'A 2023 analysis of more than 20 million deaths across the world found that hot days and days with bad air quality both resulted in higher-than-normal mortality rates. But periods in which heat and pollution are combined were even more deadly.' via @nytimes.com

Looking for a recent paper that reports on HRQoL via EQ-5D-5L/3L scores, that specifically reports on the each of the domains/levels of the EQ-5D. Preferably in a chronic disease, and also preferably US-based (but not necessary). Anyone? @euroqol.bsky.social #healtheconomics #hspr #QALYs

Our special issue, “Advancing Trust in Science: Institutional Obligations to Promote Research Integrity,” is now live in @jlme-journal.bsky.social. Check out the full line up of leading voices on spotting, addressing, and preventing misconduct. www.cambridge.org/core/journal...

I've attended this event in the past and it's absolutely fantastic! Not to mention Galway is an incredibly fun city to visit. Highly recommend!

Added a few more folks recently so thought I'd re-share. If I've missed you, reach out and I'll add you to the list! #healtheconomics

Super interesting story about Novo Nordisk and their Canadian patents. '... Novo did file a patent there for semaglutide. . .but the last time they paid the annual maintenance fee on it was 2018!' by @dereklowe.bsky.social www.science.org/content/blog...

Great and engaging panel discussion about the future of the Inflation Reduction Act by @benro.me and Chris Cai (both from @portalresearch.org), @dusetzinas.bsky.social (Vanderbilt Health Policy), and Alyson Bancroft (@p4ad.bsky.social)! #ARM25

Presenting some work on spending associated with drugs for ultra-rare diseases at the @academyhealth.bsky.social Annual Research Meeting! #arm25 @portalresearch.org

Chris Cai from @portalresearch.org presenting on private equity acquisitions of health care delivery organizations at the @academyhealth.bsky.social Annual Research Meeting. #arm25

Hey, #arm2025 attendees, @josh-caplan.bsky.social , @academyhealth.bsky.social , and @aaronecarroll.bsky.social , I made the #hspr strarter pack last year. Here are great people and orgs to follow. Enjoy Twin Cities. Still affected by fed travel limits. #hspr

Opening plenary underway with @aaronecarroll.bsky.social at the @academyhealth.bsky.social Annual Research Meeting. #arm25

Opening plenary underway with @aaronecarroll.bsky.social at the @academyhealth.bsky.social Annual Research Meeting. #arm25

On my way to the Academy Health (@academyhealth.bsky.social) Annual Research Meeting in Minneapolis with @jerryavorn.bsky.social in my ear! #arm2025 @portalresearch.org

Looking forward to attending my first ever Academy Health Annual Research Meeting with fellow @portalresearch.org members @benro.me and Chris Cai! I'll be presenting some work on spending associated with drugs for ultra-rare diseases on Sunday. See you there! #arm2025 @academyhealth.bsky.social

Great talk today by Dr Beate Sander at the annual Vancouver Health Economics Methodology Meeting on economic evidence as a component of public health decision making, with lots of discussion about the societal perspective! #healtheconomics #hta

Lots of great work showcased in this month's newsletter from @portalresearch.org! www.linkedin.com/pulse/june-2...

Just out! Sharing some new research led by @hmctaggartcowan.bsky.social from @sfu-fhs.bsky.social and BC Cancer that I was involved with. We used a discrete choice experiment to elicit patient preferences for physiotherapy services post-surgery for breast cancer. academic.oup.com/ptj/advance-...

Nice night out there.

Happy to have been able to help out with new research led by Ian Liu, with co-authors @asarpatwari.bsky.social and @akesselheim.bsky.social (@portalresearch.org). We looked at trials, labelling changes, and revenues associated with the Best Pharmaceuticals for Children Act.

An internal Celgene presentation from 2014. Celgene’s primary patent on Revlimd expired in 2019. Despite that, Celgene estimated it had a 65% chance of extending its Revlimid monopoly in the U.S. until 2026.

When research gets sidelined, it’s stalls progress, innovation, and disrupts patient care. @AcademyHealth.bsky.social is gathering stories from our field to make that case clear. If your work’s been disrupted, we want to hear from you: docs.google.com/forms/d/e/1F...

Excited to share new work in @jama.com on launch prices for cancer drugs in Medicare Part D. Prices are going up, but no trend change post-IRA. Mean monthly launch prices increased from $10,954 in 2012-2014 to $27,891 in 2023-2025. Many thanks to @arnoldventures.bsky.social for funding this work!

'The baby, now 9 ½ months old, became the first patient of any age to have a custom gene-editing treatment, according to his doctors. He received an infusion made just for him and designed to fix his precise mutation.' via @nytimes.com www.nytimes.com/2025/05/15/h...

Glad to have a chance to read through this draft guidance. The career staff have done an incredible amount of work, especially on effectuating the MFP and on the negotiation program's expansion to Part B in particular. A few brief thoughts in this thread, but longer-form analysis to come later. /1

Nice to be back! #Toronto

Lots of talk about international reference pricing today. With that in mind, sharing this great article by @leah-rand.bsky.social and @akesselheim.bsky.social from @portalresearch.org! www.valueinhealthjournal.com/article/S109...

Definitely worth a read!

Excited to get this brand new book by Jerry Avorn from @portalresearch.org in the mail today! Can't wait to give it a read! @harvardmed.bsky.social

Canada’s HTA system blends provincial autonomy with national coordination. CDA-AMC’s evolving role and the pan-Canadian Pharmaceutical Alliance are reshaping drug access and pricing. Future reforms, including national Pharmacare and global collaboration, promise more efficient and patient access.

Out today! The latest in the series "Around the World in HTAs" from the OHE (@ohenews.bsky.social) is an overview of the Canadian process that I wrote with Chris Skedgel (@chrissked.bsky.social). If you need a general overview of the HTA process in Canada, check it out! www.ohe.org/insight/arou...

Happening now! Dr Aaron Kesselheim (@akesselheim.bsky.social) providing testimony to the House Ways and Means Committee on "Lowering Costs for Patients: The Health of the Biosimilar Market." waysandmeans.house.gov/event/health... cc: @portalresearch.org

Latest edition of the PORTAL Post is out today!

The speed with which we are going backwards is beyond unsettling. Without public discourse, without debate, without Congressional input, without investigation into the impact and effect of these changes for the country ... www.bloomberg.com/opinion/feat...

Nice piece by @peterneumann11.bsky.social showing how US-based CEAs continue to use QALYs as an outcome, despite the opposition of some. cevr.tuftsmedicalcenter.org/news/the-dea...

Even if you're not new, it's always fun listening to Jeffrey Hoch talk about CEA (or health economics, generally)!

Trying to figure out how to put my #MarchMadness2025 bracket on my CV.

The Globe and Mail is hiring nine(!) digital content editors: can242.dayforcehcm.com/CandidatePor...